Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

266.57USD
11:03pm IST
Change (% chg)

$-7.91 (-2.88%)
Prev Close
$274.48
Open
$272.23
Day's High
$272.70
Day's Low
$265.13
Volume
255,816
Avg. Vol
607,863
52-wk High
$374.94
52-wk Low
$219.75

Latest Key Developments (Source: Significant Developments)

Biogen To Acquire Novel Clinical Stage Asset With Application In Alzheimer’S Disease And Parkinson’S Disease From Pfizer Inc.
Monday, 13 Jan 2020 

Jan 13 (Reuters) - Biogen Inc ::BIOGEN TO ACQUIRE NOVEL CLINICAL STAGE ASSET WITH APPLICATION IN ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE FROM PFIZER INC..BIOGEN INC - BIOGEN TO PAY PFIZER $75 MILLION UPFRONT PLUS POTENTIAL MILESTONES OF UP TO $635 MILLION, AND ROYALTIES.BIOGEN INC - BIOGEN AIMS TO INITIATE PF-05251749 PHASE 1B STUDY IN Q4 2020..BIOGEN - PLANS TO DEVELOP PHASE 1 ASSET FOR TREATMENT OF SUNDOWNING IN ALZHEIMER'S DISEASE, IRREGULAR SLEEP WAKE RHYTHM DISORDER IN PARKINSON'S DISEASE.BIOGEN INC - TRANSACTION WILL BE ACCOUNTED FOR AS AN ASSET ACQUISITION.  Full Article

Biogen Names Alfred Sandrock Vice President, Research And Development
Tuesday, 1 Oct 2019 

Oct 1 (Reuters) - Biogen Inc ::BIOGEN ANNOUNCES LEADERSHIP UPDATE.BIOGEN INC - ALFRED SANDROCK IS NAMED EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT AND CONTINUES AS CHIEF MEDICAL OFFICER.BIOGEN INC - ALPHONSE GALDES APPOINTED EXECUTIVE VICE PRESIDENT, PHARMACEUTICAL OPERATIONS AND TECHNOLOGY.BIOGEN INC - MICHAEL EHLERS, EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT HAS DECIDED TO LEAVE BIOGEN.  Full Article

Biogen Says Diroximel Fumarate Demonstrated Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis
Tuesday, 30 Jul 2019 

July 30 (Reuters) - Biogen Inc ::DIROXIMEL FUMARATE DEMONSTRATED SIGNIFICANTLY IMPROVED GASTROINTESTINAL TOLERABILITY PROFILE COMPARED TO DIMETHYL FUMARATE IN PATIENTS WITH MULTIPLE SCLEROSIS.BIOGEN INC - DISCONTINUATIONS DUE TO GI EVENTS WERE LESS THAN 1% FOR DIROXIMEL FUMARATE.BIOGEN - DIROXIMEL FUMARATE DEMONSTRATED STATISTICALLY SUPERIOR GI TOLERABILITY COMPARED TO DIMETHYL FUMARATE ON EVOLVE-MS-2 STUDY'S PRIMARY ENDPOINT.BIOGEN INC - BIOGEN INTENDS TO MARKET DIROXIMEL FUMARATE UNDER CONDITIONALLY APPROVED BRAND NAME VUMERITY.BIOGEN INC - OVERALL PROPORTION OF PATIENTS WITH AES LEADING TO STUDY DISCONTINUATION WERE 1.6% FOR DIROXIMEL FUMARATE AND 6.0% FOR DIMETHYL FUMARATE.BIOGEN INC - FURTHER ANALYSIS OF DATA FROM EVOLVE-MS-2 STUDY IS ONGOING AND WILL BE PRESENTED AT A FUTURE SCIENTIFIC FORUM..  Full Article

Skyhawk Therapeutics Says To Expand Collaboration Agreement With Biogen
Monday, 8 Jul 2019 

July 8 (Reuters) - Skyhawk Therapeutics::SKYHAWK THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION AGREEMENT WITH BIOGEN.SKYHAWK THERAPEUTICS, INC - TO EXPAND COLLABORATION WITH BIOGEN TO DEVELOP NOVEL SMALL MOLECULE RNA SPLICING MODIFIERS FOR DISEASE TARGETS.SKYHAWK THERAPEUTICS - BIOGEN TO PAY SKYHAWK ADDITIONAL UPFRONT AND POTENTIAL FUTURE MILESTONE PAYMENTS AND ROYALTIES.  Full Article

Biogen Announces European Label Update For Spinraza
Saturday, 29 Jun 2019 

June 29 (Reuters) - Biogen Inc ::BIOGEN ANNOUNCES EUROPEAN LABEL UPDATE FOR SPINRAZA (NUSINERSEN) WHICH INCLUDES LONGER-TERM DATA ACROSS A BROAD RANGE OF AGES AND TYPES OF SPINAL MUSCULAR ATROPHY.NO NEW SAFETY CONCERNS WERE IDENTIFIED.  Full Article

ISS And Glass Lewis Recommend Nightstar Shareholders Vote "For" Proposed Acquisition By Biogen
Friday, 26 Apr 2019 

April 26 (Reuters) - Nightstar Therapeutics PLC ::LEADING PROXY ADVISORY FIRMS ISS AND GLASS LEWIS RECOMMEND NIGHTSTAR SHAREHOLDERS VOTE “FOR” PROPOSED ACQUISITION BY BIOGEN.  Full Article

Nightstar Therapeutics PLC Reaches Agreement To Be Acquired By Biogen
Monday, 4 Mar 2019 

March 4 (Reuters) - Nightstar Therapeutics PLC ::NIGHTSTAR THERAPEUTICS PLC REACHES AGREEMENT TO BE ACQUIRED BY BIOGEN.  Full Article

Biogen Announces Agreement To Acquire Nightstar Therapeutics
Monday, 4 Mar 2019 

March 4 (Reuters) - Biogen Inc ::BIOGEN ANNOUNCES AGREEMENT TO ACQUIRE NIGHTSTAR THERAPEUTICS TO ESTABLISH CLINICAL PIPELINE OF GENE THERAPY CANDIDATES IN OPHTHALMOLOGY.THIS OFFER REPRESENTS A TOTAL TRANSACTION VALUE OF APPROXIMATELY $800 MILLION ON A FULLY DILUTED BASIS.SAYS BIOGEN TO ACQUIRE NIGHTSTAR THERAPEUTICS FOR $25.50 PER SHARE.ACQUISITION OF NST IS PLANNED TO BE FUNDED THROUGH AVAILABLE CASH AND ACCOUNTED FOR AS AN ACQUISITION OF A BUSINESS.  Full Article

Alkermes And Biogen Announce U.S. FDA Acceptance Of Diroximel Fumarate New Drug Application For Multiple Sclerosis
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Biogen Inc ::ALKERMES AND BIOGEN ANNOUNCE U.S. FOOD AND DRUG ADMINISTRATION ACCEPTANCE OF DIROXIMEL FUMARATE NEW DRUG APPLICATION FOR MULTIPLE SCLEROSIS.BIOGEN INC - IF APPROVED, BIOGEN INTENDS TO MARKET DIROXIMEL FUMARATE UNDER BRAND NAME VUMERITY.BIOGEN INC - NDA HAS BEEN ASSIGNED A PDUFA (PRESCRIPTION DRUG USER FEE ACT) TARGET ACTION DATE IN Q4 OF 2019.BIOGEN INC - ALKERMES IS SEEKING APPROVAL OF DIROXIMEL FUMARATE UNDER 505(B)(2) REGULATORY PATHWAY, REFERENCING BIOGEN'S DIMETHYL FUMARATE DATA.  Full Article

Biogen Says Continues To Diligently Evaluate New Opportunities For More Potential Business Development And M&A
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Biogen Inc ::CEO SAYS CO CONTINUES TO DILIGENTLY EVALUATE NEW OPPORTUNITIES FOR MORE POTENTIAL BUSINESS DEVELOPMENT AND M&A - CONF CALL.EXPECTS PHASE 3 DATA FOR ALZHEIMER'S TREATMENT ADUCANUMAB IN EARLY 2020 - CONF CALL.CFO SAYS EXPECTS GLOBAL SPINRAZA REVENUE TO BE RELATIVELY STABLE IN Q1, 2019 VERSUS Q4, 2018 - CONF CALL.CFO EXPECTS 2019 GLOBAL SPINRAZA REVENUES TO GROW IN MID-TO HIGH-TEENS - CONF CALL.CFO EXPECTS DOUBLE-DIGIT REVENUE GROWTH IN BIOSIMILAR BUSINESS IN 2019, PRIMARILY DRIVEN BY LAUNCH OF IMRALDI - CONF CALL.SAYS MULTIPLE SCLEROSIS BUSINESS GROWTH TRENDS TO CONTINUE IN 2019; EXPECTS PRICING PRESSURES OUTSIDE THE U.S. - CONF CALL.  Full Article

Photo

Alzheimer's drug from Biogen to get speedy U.S. review

The U.S. Food and Drug Administration will conduct an expedited review of an experimental Alzheimer's drug from Biogen Inc and Japan's Eisai Co Ltd, the companies said on Friday, the first application in 17 years to be reviewed by the agency for a treatment of the mind-robbing disease.